Ravulizumab

• CAT Number: I042227
• CAS Number: 1803171-55-2
• Purity: ≥95%

Ravulizumab（Cat No.:I042227）is a monoclonal antibody designed to inhibit the complement protein C5, which plays a key role in the immune system’s response and inflammation. By blocking C5, Ravulizumab prevents the formation of the membrane attack complex, reducing tissue damage associated with complement activation. It is primarily used in the treatment of rare, chronic conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Clinical studies have shown that Ravulizumab offers a longer duration of action compared to other C5 inhibitors, providing patients with a more convenient treatment option.